Is BDX a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Becton, Dickinson and Company (BDX) rests on A simpler, pure-play medtech after the Waters separation: The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. The bear case rests on the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Analysts covering it publish targets from $195.00 to $242.00 against a $216.47 share price on November 16, 2026, so even the professionals disagree by 21% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
BDX key stats
At $216.47 on November 16, 2026, Becton, Dickinson and Company (BDX) has a market cap of $59.0B, a P/E of 42.8 on trailing earnings (15.2 on forward earnings) and a dividend yield of 1.96%.
- Market cap
- $59.0B
- P/E (trailing)
- 42.8
- P/E (forward)
- 15.2
- EPS (trailing 12 months)
- $5.06
- Price to book
- 2.4
- Dividend yield
- 1.96%
- Beta
- 0.28
Market cap, P/E and yield are measured at the $216.47 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Becton, Dickinson and Company (BDX)?
The last two weeks for Becton, Dickinson and Company, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- BDX closed at $216.47 on November 16, 2026, up 0.6% over the past five trading days (from $215.25).
- On November 5, 2026, Becton, Dickinson and Company filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 10, 2026, Barclays raised its target to $195.00 from $165.00 (Underweight).
- On November 7, 2026, JP Morgan raised its target to $202.00 from $170.00 (Neutral).
- On November 6, 2026, Citigroup raised its target to $241.00 from $208.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Becton, Dickinson and Company, known as BD, is one of the largest medical technology companies in the world, founded in 1897 and headquartered in Franklin Lakes, New Jersey. Most of what it sells is consumable rather than capital equipment: needles and syringes, IV catheters and vascular access sets, infusion pumps and their disposable sets, surgical and specimen-collection products, prefillable syringes sold to pharmaceutical companies, and interventional devices used in urology, peripheral vascular and surgery. That mix matters because consumables are consumed and reordered, so a large share of revenue recurs each year regardless of hospital capital budgets. Following the February 2026 separation, BD reports in four segments: Medical Essentials (~$1.68 billion in the June 2026 quarter), Interventional (~$1.41 billion), Connected Care (~$1.22 billion) and BioPharma Systems (~$0.67 billion). The defining corporate event was the Reverse Morris Trust transaction that moved BD's Biosciences and Diagnostic Solutions businesses into Waters Corporation, which closed on February 9, 2026. BD shareholders received roughly 0.135 shares of Waters for each BD share held as of February 5, 2026 and ended up owning about 39.2% of the combined Waters, while BD itself received about $4 billion in cash. The divested business was valued at roughly $18.8 billion. Anyone comparing BDX financials across periods needs to be careful, because the separated business is now reported as discontinued operations: trailing revenue from continuing operations sits near $20.8 billion, while pre-separation fiscal 2025 revenue as originally reported was about $21.8 billion. In the third quarter of fiscal 2026, reported on August 6, 2026, BD posted about $5.0 billion of revenue (up ~5.4% as reported and ~4.4% on a currency-neutral basis), GAAP diluted EPS from continuing operations of ~$1.64 and adjusted diluted EPS of ~$3.23, and raised the top end of its full-year adjusted EPS guidance to a range of ~$12.62 to ~$12.72. The market has rewarded the simpler company. As of October 16, 2026 BDX closed at about $192.50, up about 25.6% year to date, about 25% over three months and about 32% over one year, close to its 52-week high of roughly $196 (the 52-week low was about $128). Adjusted EPS has beaten consensus in each of the last four quarters, most recently $3.23 against about $3.14 for the June quarter. In October BD also reported nine-month AGILITY trial data for its Revello stent in peripheral artery disease, a pipeline item for the Interventional segment. The company reports fiscal fourth-quarter and full-year 2026 results on November 5, 2026, with consensus at about $5.1 billion of revenue and $4.07 of adjusted EPS.
The bull case: what would have to be true for $242.00
The most optimistic published target on BDX is $242.00, +11.8% from the $216.47 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. A simpler, pure-play medtech after the Waters separation
The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. Management argues the remaining portfolio has more consistent growth, better cash conversion and a cleaner story for investors, and the ~$4 billion of cash received gives room for debt paydown and buybacks. The test over the next several quarters is whether the residual company actually delivers the mid-single-digit organic growth and margin expansion that justified breaking the company up.
2. BioPharma Systems and injectable drug delivery
BioPharma Systems makes prefillable syringes, pens and self-injection systems sold to pharmaceutical customers, which puts BD in the supply chain for the GLP-1 obesity and diabetes drugs and for the broader shift toward biologics delivered by injection at home. This segment grew about 6.6% as reported in the June 2026 quarter, the fastest of the four. The flip side is customer concentration: a small number of very large pharma buyers drive the order book, and their capacity and inventory decisions move BD's results.
3. Interventional and Connected Care growth platforms
Interventional (peripheral vascular, urology, surgery) and Connected Care (infusion systems, medication management, dispensing) are the segments BD points to for above-portfolio growth, and both grew in the mid-single digits in the June 2026 quarter. Connected Care in particular benefits from the return of the Alaris infusion pump to the US market after the long FDA remediation, which converts a former liability into a placement and consumables opportunity. Recurring disposable sets attached to installed pumps are the durable part of that economics. In October 2026 BD reported nine-month AGILITY trial results for the Revello stent in peripheral artery disease, one more clinical data point for the Interventional growth story.
4. Valuation reset and capital returns
After a roughly 26% rise in 2026, BDX trades near ~$192.50 per share for a market capitalization around ~$52 billion, or roughly 14.5 times forward earnings, still a discount to higher-growth device peers but a narrower one than earlier in the year. The company pays a dividend of ~$4.20 per share (a yield near ~2.2% at the higher price) and has a long record of annual increases. Whether the discount narrows further depends on management sustaining organic growth and free cash flow now that the portfolio-reshaping story is done.
The bear case: what would have to be true for $195.00
The most pessimistic published target is $195.00, -9.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Becton, Dickinson and Company is worth if the risks below bite instead of the drivers above.
The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Quality and regulatory risk is real and recurring for a device maker at this scale, including a 2026 voluntary recall of certain intraosseous vascular access needle sets and the multi-year FDA remediation history of the Alaris infusion pump. Customer power is a structural pressure, because hospitals buy through group purchasing organizations and integrated delivery networks that negotiate hard on commodity consumables such as syringes and catheters, while China volume-based procurement compresses pricing in that market. Tariffs, freight and input costs affect a business that ships enormous physical volumes across borders, and currency swings move reported results given large international exposure. Finally, the separation itself introduces execution risk: stranded costs, dis-synergies and a smaller revenue base against the debt taken on before the split all have to be managed, and the comparison history is now discontinuous, which makes trend analysis harder. After a 25% three-month rally to near its 52-week high, the stock also carries more expectation than it did earlier in 2026, so a soft fiscal 2027 outlook on November 5 would land on a fuller valuation.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding BDX already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on BDX
14 analysts cover BDX, with an average target of $226.14 (+4.5% against $216.47) and a split of 9 buy, 6 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the BDX forecast and price target page.
How is BDX valued?
Market cap, P/E and dividend yield at today's price are in the BDX key stats above. The business figures below come from Becton, Dickinson and Company's reported results as of October 2026 and change when it next reports.
- Revenue (TTM, continuing operations): ~$20.8 billion
- Q3 fiscal 2026 revenue (quarter ended June 2026): ~$5.0 billion, up ~5.4% as reported and ~4.4% currency-neutral
- Q3 fiscal 2026 EPS: ~$1.64 GAAP diluted from continuing operations, ~$3.23 adjusted (vs ~$3.14 estimate)
- Fiscal 2026 guidance (adjusted diluted EPS): ~$12.62 to ~$12.72
- Margins (gross / operating): ~47% / ~16%
- Dividend: ~$4.20 per share, yield ~2.2%
As of October 2026: All figures are approximate and tied to the asOf date; check live numbers before acting on any of them. The wide gap between the trailing GAAP multiple (~45x) and the forward multiple (~14.5x) is mostly an artifact of separation charges, intangible amortization and discontinued-operations accounting depressing reported GAAP earnings, which is why BD and most analysts discuss adjusted EPS. The stock's 2026 rally has lifted the forward multiple from about 13-14x in August toward 14.5x, and fiscal fourth-quarter results with a likely first look at fiscal 2027 arrive on November 5, 2026.
How do you decide if BDX is a buy?
Whether BDX is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BDX indirectly through an index or sector ETF before adding more.
What would change your mind on BDX
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: A simpler, pure-play medtech after the Waters separation stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the BDX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BDX against your real portfolio and see your actual exposure before deciding.
Your questions about Becton, Dickinson and Company
Ask Walnut's AI anything about BDX and see how it fits what you own.
FAQ
Is BDX a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on A simpler, pure-play medtech after the Waters separation, with revenue (ttm, continuing operations) at ~$20.8 billion. The bear case rests on the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Analysts covering it are spread from $195.00 to $242.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell BDX?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $195.00, -9.9% from the $216.47 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for BDX?
+
A simpler, pure-play medtech after the Waters separation. The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. The most optimistic analyst target on BDX is $242.00, +11.8% from the $216.47 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for BDX?
+
The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Quality and regulatory risk is real and recurring for a device maker at this scale, including a 2026 voluntary recall of certain intraosseous vascular access needle sets and the multi-year FDA remediation history of the Alaris infusion pump. Customer power is a structural pressure, because hospitals buy through group purchasing organizations and integrated delivery networks that negotiate hard on commodity consumables such as syringes and catheters, while China volume-based procurement compresses pricing in that market. Tariffs, freight and input costs affect a business that ships enormous physical volumes across borders, and currency swings move reported results given large international exposure. Finally, the separation itself introduces execution risk: stranded costs, dis-synergies and a smaller revenue base against the debt taken on before the split all have to be managed, and the comparison history is now discontinuous, which makes trend analysis harder. After a 25% three-month rally to near its 52-week high, the stock also carries more expectation than it did earlier in 2026, so a soft fiscal 2027 outlook on November 5 would land on a fuller valuation. The most pessimistic published target is $195.00, -9.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Becton, Dickinson and Company do?
+
Becton, Dickinson and Company (BD) is a US medical technology maker of syringes, IV catheters, infusion systems, prefillable drug-delivery devices and interventional products.
What would have to change for BDX to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (A simpler, pure-play medtech after the Waters separation) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What company is BDX stock?
+
BDX is the New York Stock Exchange ticker for Becton, Dickinson and Company, usually called BD. It is a medical technology company founded in 1897 and based in Franklin Lakes, New Jersey, that makes syringes, needles, IV catheters, infusion systems, prefillable drug-delivery devices and interventional products. After the February 2026 separation it operates in four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.
Did Becton Dickinson spin off its diagnostics business?
+
Yes. BD completed the separation of its Biosciences and Diagnostic Solutions businesses and their combination with Waters Corporation on February 9, 2026, structured as a Reverse Morris Trust. BD shareholders received about 0.135 shares of Waters for each BD share held as of February 5, 2026 and ended up owning roughly 39.2% of the combined company, while BD received about $4 billion in cash. The divested business was valued at roughly $18.8 billion.
Is BDX a good stock to buy right now?
+
That depends on your goals, time horizon and risk tolerance, and nothing here is investment advice. The constructive case is a simpler post-separation medtech with heavily recurring consumables revenue, mid-single-digit organic growth, roughly 14.5 times forward earnings after a ~26% gain in 2026 and a long dividend record. The cautious case is slow growth against faster-growing device peers, persistent mesh and IVC-filter product liability, hospital pricing pressure and the execution risk of standing up a smaller company. Weigh both against the rest of your portfolio.
Walnut is informational, not investment advice, and gives no verdict on BDX. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.